Human Genome Sciences is developing a drug, Albuferon, a combination of the human protein albumin and interferon.

FORBES: Magazine Article

Patients in a midstage trial of Albuferon reported better quality of life, although the experiment is still at an interim stage.

FORBES: Magazine Article

McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences.

FORBES

Human Genome Sciences (nasdaq: HGSI - news - people ) is developing a drug, Albuferon, a combination of the human protein albumin and interferon.

FORBES: Saving Your Liver

McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences (nasdaq: HGSI - news - people ).

FORBES: Gilead's Half-Empty Pipeline

In June Human Genome Sciences partnered with Swiss pharmaceutical giant Novartis to jointly commercialize Albuferon in the U.S. Novartis will sell the drug outside the U.S. Of course, the risk for investors is that late-stage clinical trials could show it to be a flop.

FORBES: Magazine Article

In June Human Genome Sciences partnered with Swiss pharmaceutical giant Novartis (nyse: NVS - news - people ) to jointly commercialize Albuferon in the U.S. Novartis will sell the drug outside the U.S. Of course, the risk for investors is that late-stage clinical trials could show it to be a flop.

FORBES: Saving Your Liver